These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 15764221

  • 1. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer.
    Fokdal L, Høyer M, von der Maase H.
    Acta Oncol; 2004; 43(8):749-57. PubMed ID: 15764221
    [Abstract] [Full Text] [Related]

  • 2. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B, Félix-Faure C, Davin JL, Choquenet C, Alfonsi M, Reboul F.
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [Abstract] [Full Text] [Related]

  • 3. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
    Chauvet B, Brewer Y, Félix-Faure C, Davin JL, Choquenet C, Reboul F.
    J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
    [Abstract] [Full Text] [Related]

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 5. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI, Tsolos C, Touloupidis S.
    Urology; 2007 Feb 15; 69(2):245-50. PubMed ID: 17320657
    [Abstract] [Full Text] [Related]

  • 6. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy.
    Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, Van der Voet J, Collins CD, Khoo VS, Read GR.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):197-207. PubMed ID: 15093917
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
    Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK.
    Urol Oncol; 2007 May 01; 25(4):303-9. PubMed ID: 17628296
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS.
    J Urol; 2009 Feb 01; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [Abstract] [Full Text] [Related]

  • 11. Clinical radiobiology of stage T2-T3 bladder cancer.
    Majewski W, Maciejewski B, Majewski S, Suwinski R, Miszczyk L, Tarnawski R.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):60-70. PubMed ID: 15337540
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
    Tran E, Souhami L, Tanguay S, Rajan R.
    Am J Clin Oncol; 2009 Aug 01; 32(4):333-7. PubMed ID: 19381080
    [Abstract] [Full Text] [Related]

  • 16. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI.
    J Clin Oncol; 2005 Sep 20; 23(27):6533-9. PubMed ID: 16116151
    [Abstract] [Full Text] [Related]

  • 17. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG.
    J Urol; 2006 Aug 20; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [Abstract] [Full Text] [Related]

  • 18. Prognostic factors in oropharyngeal cancer--analysis of 627 cases receiving definitive radiotherapy.
    Agarwal JP, Mallick I, Bhutani R, Ghosh-Laskar S, Gupta T, Budrukkar A, Murthy V, Sengar M, Dinshaw KA.
    Acta Oncol; 2009 Aug 20; 48(7):1026-33. PubMed ID: 19363712
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer.
    Piet AH, Hulshof MC, Pieters BR, Pos FJ, de Reijke TM, Koning CC.
    Strahlenther Onkol; 2008 Jun 20; 184(6):313-8. PubMed ID: 18535807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.